Dear Madam or Sir, Dear shareholder
We are delighted to introduce you to these pages dedicated solely to you. First of all, on behalf of the entire team, I would like to thank you for the trust you’ve put in us and for your contribution to the success of our IPO on Euronext Brussels and Euronext Paris.
The funds raised will support the strong momentum established by our achievements and will allow our products to complete all planned development phases.
Our product pipeline currently consists of two product candidates based on the ASIT+TM platform targeting respiratory allergy with the highest prevalence. gp-ASIT+TM, is intended for use in the treatment of allergy to grass pollen. The second product candidate, hdm-ASIT+TM, targets house dust mite allergy. Altogether, our products would serve a potential market of around 12 million patients1 who are currently not satisfied by existing allergy therapies in Europe and the United States.
We firmly believe that thanks to your support, our promising product portfolio will provide these patients with simpler and more rapid treatment option and we will be able to explore the potential of our technological platform for other types of allergies.
Thierry Legon, Chief Executive Officer
1 Based on “The prevalence of the sensitization by allergen” - EU: Bauchau & Durham 2004; US: Nathan 1997 & 2008.